Nanotechnology-based Intranasal Drug Delivery Systems: A Review

Abstract

An experimental study has focused on developing a different approach to systemic oral along with parenteral administration in order to overcome their common drawbacks, including hepatic first-pass, which reduces drug bioavailability following oral administration, off-target effects, low patient compliance, along with a slow onset of pharmacological action through first-aid cases. Novel drug delivery systems (DDS), mostly composed of polymers and biocompatible lipid materials, have significantly boosted this sector in recent years. The previously intranasal (IN) method of delivery is an acceptable non-invasive option. It is ideal for self-administration since the medication quickly enters the circulation, eliminating the initial pass effect, and it may additionally reach the brain’s cortex directly by crossing the blood-brain barrier (BBB). The combination of the IN route alongside DDS can, therefore, become a successful method for regulated drug administration, particularly when a rapid impact is sought or required. This study seeks to analyze the scientific literature on IN-DDS and its various routes for consumption (systemic, topical, pulmonary, and nose-to-brain). In this regard, the intranasal route offers a viable pathway for medication delivery reaching the brain because of its distinct anatomical characteristics. Nanoparticle-based technologies, in particular, have proven a remarkable ability to overcome the limitations of the intranasal route to induce drug accumulation throughout the brain despite avoiding systemic dissemination